199 related articles for article (PubMed ID: 8225242)
1. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Hurlimann J; Gebhard S; Gomez F
Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
[TBL] [Abstract][Full Text] [Related]
2. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
[TBL] [Abstract][Full Text] [Related]
4. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
5. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
6. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A
Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
[TBL] [Abstract][Full Text] [Related]
7. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
8. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
11. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
12. Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer.
Nakopoulou L; Lazaris AC; Baltas D; Giannopoulou I; Kavantzas N; Tzonou A
Virchows Arch; 1995; 427(1):33-40. PubMed ID: 7551343
[TBL] [Abstract][Full Text] [Related]
13. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
14. [Cytosolic concentrations of cathepsin D in 88 infiltrating ductal breast carcinomas having negative estrogen and progesterone receptors. Correlation with other clinical and biological parameters].
Ruibal A; Arias J; Lapeña G; García Díez S; Tejerina A
Rev Esp Med Nucl; 2001 Jun; 20(4):332-3. PubMed ID: 11940423
[No Abstract] [Full Text] [Related]
15. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population.
Chaubert P; Bouzourene H; Saraga E
Mod Pathol; 1996 Mar; 9(3):189-93. PubMed ID: 8685212
[TBL] [Abstract][Full Text] [Related]
16. [Hormone-dependent, diploid, infiltrating ductal breast carcinomas less than 2 cm in size: influence of an exclusive and moderate cellular proliferation on the clinicobiological features and recurrences of these malignant tumors].
Ruibal A; Arias JI
Rev Esp Med Nucl; 2002; 21(6):437-8. PubMed ID: 12425893
[No Abstract] [Full Text] [Related]
17. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas.
Weber-Chappuis K; Bieri-Burger S; Hurlimann J
Eur J Cancer; 1996 Sep; 32A(10):1686-92. PubMed ID: 8983275
[TBL] [Abstract][Full Text] [Related]
18. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
19. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
Ruibal A; Garrido-Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
[TBL] [Abstract][Full Text] [Related]
20. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
Ruibal A; Arias J; del Río MC; San Román JM; Lapeña G; Pardo C; Tejerina A
Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]